L3VLUP
ProSign in

JANX in the 13F filings

Janux Therapeutics Inc · CUSIP 47103J105

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q3 2023Q2 2023
Quarter end
30 Jun 2023
the date the book describes
Filed
14 Aug 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 1 listed it in both
Shares listed
137,300
combined, among listed positions
Reported value
$1.6m
combined, at the quarter end

Managers listing JANX in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Woodline Partners LP137,300$1.6munder 0.1%Held014 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

0246820222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
JANX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20211$8.3mn.a.n.a.
Q3 20211$6.5mn.a.n.a.
Q4 20211$5.5mn.a.n.a.
Q1 20221$4.0mn.a.n.a.
Q2 20221$3.5mn.a.n.a.
Q3 20221$5.4mn.a.n.a.
Q4 20221$6.7mn.a.n.a.
Q1 20231$1.7mn.a.n.a.
Q2 20231$1.6mn.a.n.a.
Q3 20231$864kn.a.n.a.
Q1 20243$76m30
Q2 20243$98m22
Q3 20245$218m41
Q4 20248$850m61
Q1 20253$174m12
Q2 20254$182m12
Q3 20253$182m13
Q4 20252$88m216
Q1 20261$58m1014
Q2 20261$1.4m1413

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

JANX and LLY →JANX and JNJ →JANX and VRTX →Choose a stock to compare with JANX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own JANX, latest filings →Back to the 13F Explorer →